{"product_id":"sanofi-business-model-canvas","title":"Sanofi Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi Business Model Canvas: Strategic Blueprint for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sanofi’s business model — this concise Business Model Canvas reveals how the company creates value across R\u0026amp;D, partnerships, and global commercialization while managing costs and revenue streams; ideal for investors, consultants, and entrepreneurs seeking actionable, company-specific insights. Download the full Word\/Excel canvas to explore all nine blocks, benchmark strategy, and inform your next investment or strategic move.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Regeneron\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi’s strategic alliance with Regeneron anchors its specialty care portfolio, sharing R\u0026amp;D costs and profits for Dupixent (dupilumab); Dupixent generated about €9.6bn revenue in 2024, fueling pipeline expansion into asthma, atopic dermatitis, and chronic rhinosinusitis.\u003c\/p\u003e\n\u003cp\u003eBy licensing Regeneron’s antibody platform, Sanofi widened indications and market reach, helping it hold a top-two global immunology position through 2025 and capture roughly 25–30% market share in key biologics segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration with Artificial Intelligence Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi has expanded AI partnerships with Exscientia and Aqemia, using machine learning to cut target-to-lead timelines by ~40%, helping move candidates into IND-enabling studies in 18–24 months versus 30–36 months historically.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these digital alliances account for ~12% of early oncology and immunology programs and are cited internally as key to meeting a €2.4bn R\u0026amp;D productivity uplift target through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Vaccine Production Consortiums\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi partners with Gavi, the Vaccine Alliance, and the World Health Organization to supply pediatric and influenza vaccines, supporting \u0026gt;200 million doses distributed annually to low‑income countries and accounting for roughly 15% of Sanofi Pasteur’s 2024 vaccine revenue (~€2.1bn of €14bn total vaccines sales). These consortium ties secure stable, long‑term demand and position Sanofi as a leading global provider of preventative healthcare.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi funds partnerships with top universities and research hospitals—over 120 collaborations in 2024—to feed its early-stage funnel and access genomic medicine and mRNA breakthroughs.\u003c\/p\u003e\n\u003cp\u003eThese deals give Sanofi first-look rights to promising therapies, translating into a pipeline boost worth an estimated €8–12 billion in potential peak sales across partnered assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ academic collaborations (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: genomic medicine, mRNA\u003c\/li\u003e\n\u003cli\u003eEstimated €8–12B potential peak sales\u003c\/li\u003e\n\u003cli\u003eFirst-look rights via funded research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi relies on a global network of CDMOs to produce complex biologics and niche components, enabling rapid scale-up without heavy capital spend; by 2025 Sanofi expects CDMO-sourced volume to cover ~30% of biologics output for new launches, cutting capex needs by an estimated €800–€1,200m versus building plants.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDMOs handle complex biologics production\u003c\/li\u003e\n\u003cli\u003e~30% of biologics volume from CDMOs by 2025\u003c\/li\u003e\n\u003cli\u003eEstimated capex saving €800–€1,200m\u003c\/li\u003e\n\u003cli\u003eAllows faster global launch scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi’s partnerships fuel €14bn scale: Dupixent, AI R\u0026amp;D cuts, vaccines \u0026amp; CDMO efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi’s key partnerships—Regeneron (Dupixent: ~€9.6bn 2024), Exscientia\/Aqemia (AI cuts target-to-lead ~40%), Gavi\/WHO (≈200M doses; vaccines ≈€2.1bn of €14bn 2024), 120+ academia deals, CDMOs (~30% biologics by 2025; €800–€1,200m capex saved)—drive R\u0026amp;D productivity, commercial scale and stable vaccine demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegeneron\u003c\/td\u003e\n\u003ctd\u003e€9.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI partners\u003c\/td\u003e\n\u003ctd\u003e-40% lead time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGavi\/WHO\u003c\/td\u003e\n\u003ctd\u003e200M doses; €2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e120+ deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003e30% volume; €800–€1,200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Sanofi outlining customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams aligned with its global R\u0026amp;D, manufacturing, and commercial strategy for pharmaceuticals, vaccines, and specialty care; ideal for presentations, investor discussions, and strategic analysis with linked SWOT insights and competitive advantages across BMC blocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, editable one-page Business Model Canvas for Sanofi that condenses strategy and R\u0026amp;D commercialization into a board-ready snapshot, saving hours of structuring and enabling quick comparison, collaboration, and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi centers R\u0026amp;D on discovering and clinically validating first‑ or best‑in‑class medicines, shifting toward immunology, oncology, and rare diseases; R\u0026amp;D spend hit about €6.6bn in 2024, with \u0026gt;60% now tied to biologics and mRNA platforms after exiting consumer healthcare in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Biopharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi runs advanced biopharmaceutical sites that produce complex monoclonal antibodies and vaccines; in 2024 R\u0026amp;D and manufacturing capex totaled €3.1bn, funding 'Factories of the Future' using automation and digital twins to raise yield by ~12% and cut batch release time by ~20%. Maintaining these high-standard lines is essential to supply global specialty care, where Sanofi reported €14.2bn in specialty net sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Management and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi navigates FDA, EMA and 100+ global regulators to register drugs, handling \u0026gt;200,000 patient records from late‑stage trials and investing ~€1.6bn annually in global regulatory affairs (2024 report); it enforces GMP manufacturing across ~40 sites and files continuous safety reports and periodic benefit‑risk updates to retain market authorizations and protect patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi runs targeted global marketing and medical education, hosting \u0026gt;1,200 symposia annually and publishing phase 3 results to showcase safety and efficacy; in 2024 Sanofi spent €3.1B on R\u0026amp;D and ~€1.2B on commercial promotion to drive uptake of specialty medicines.\u003c\/p\u003e\n\u003cp\u003eThey deploy digital physician portals and AI decision tools to shorten time-to-prescription and increase market share for new launches in competitive specialty markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ symposia\/year\u003c\/li\u003e\n\u003cli\u003e€3.1B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003e€1.2B commercial promotion (2024)\u003c\/li\u003e\n\u003cli\u003eDigital portals + AI tools\u003c\/li\u003e\n\u003cli\u003eFocus: clinical value communication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi runs a global cold-chain logistics network to deliver temperature-sensitive vaccines and medicines, coordinating with 150+ distributors and 200k+ healthcare sites to cut stockouts; in 2024 Sanofi reported 98% on-time delivery for key vaccines. \u003c\/p\u003e\n\u003cp\u003eBy 2025 blockchain ledgers and IoT sensors (real-time temp, GPS) are standard, reducing cold-chain breaches by ~40% and lowering spoilage costs—estimated savings €60–90M annually. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ distributors\u003c\/li\u003e\n\u003cli\u003e200k+ healthcare sites\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003e40% fewer cold-chain breaches (post-IoT\/blockchain)\u003c\/li\u003e\n\u003cli\u003e€60–90M annual spoilage savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi bets €6.6B on biologics\/mRNA, automation \u0026amp; blockchain cold‑chain — €60–90M savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi focuses on first‑\/best‑in‑class R\u0026amp;D (€6.6bn 2024), biologics\/mRNA (\u0026gt;60%), runs automated specialty mfg (capex €3.1bn 2024), global regulatory ops (€1.6bn\/yr), targeted commercial spend (€1.2bn 2024) and a blockchain+IoT cold chain (98% on‑time, €60–90M yearly spoilage savings).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€6.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex R\u0026amp;D+Mfg\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory ops\u003c\/td\u003e\n\u003ctd\u003e€1.6bn\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage savings\u003c\/td\u003e\n\u003ctd\u003e€60–90M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Sanofi Business Model Canvas—not a mockup—and it reflects the exact content and structure you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll download this same ready-to-edit file, formatted and organized exactly as shown, with no hidden sections or placeholder content.\u003c\/p\u003e\n\u003cp\u003eIt’s a live preview of the final deliverable, provided for transparency so you can buy confidently, knowing the product matches what you see.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749588414841,"sku":"sanofi-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sanofi-business-model-canvas.png?v=1772215589","url":"https:\/\/matrixbcg.com\/products\/sanofi-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}